Company Overview - N Hanbang has been listed today with an opening price of 49.00 yuan, representing an increase of 115.20% from its issue price [2] - The company focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, application technology services, and related technical solutions [2] Financial Highlights - The total number of shares issued by the company is 22 million, with an online issuance of 7.04 million shares at an issue price of 22.77 yuan per share [2] - The issue price corresponds to a price-to-earnings (P/E) ratio of 26.35, compared to the industry average P/E ratio of 28.04 [2] - The total funds raised from the initial public offering (IPO) amount to 501 million yuan, which will be used for working capital, the construction of a chromatography separation equipment R&D center, and the production projects for laboratory chromatography separation and purification instruments [2] Recent IPO Performance - N Hanbang's first-day performance is notable, with a significant increase of 115.20% [2] - Other recent IPOs on the same day include N Zairun, which saw a rise of 98.12%, and Tian Gong Co., which experienced a dramatic increase of 458.63% [3]

Core Viewpoint - Hanbang Technology has successfully transitioned from a chromatography consumables agent to a leading domestic manufacturer of preparative chromatography equipment, becoming the first stock of chromatography equipment on the Sci-Tech Innovation Board [3][4]. Company Development - Established in 1998, Hanbang Technology initially focused on the agency sales of chromatography consumables, facing market saturation by 2006, which prompted a shift towards independent research and development [4]. - The company launched its first dynamic axial compression column in 2005, and by 2012, revenue from self-developed products surpassed that from agency sales [4][5]. - By 2024, Hanbang Technology was recognized as a "little giant" enterprise by the Ministry of Industry and Information Technology, ranking first in the domestic production-grade small molecule liquid chromatography system market [5]. Talent and R&D - Since 2010, Hanbang Technology has focused on attracting and retaining R&D talent, forming a technical team of 141 members by 2024, including 5 core technical personnel [5]. - The company implements various incentive measures, such as salary bonuses and stock options, to stabilize and develop its core technical team [5]. Market Position and Clientele - Hanbang Technology primarily serves the pharmaceutical industry, with notable clients including domestic giants like Heng Rui Medicine and international pharmaceutical equipment integrators [6][7]. - The company emphasizes the importance of high-purity separation and purification technologies, which are increasingly demanded due to stringent regulatory requirements [7]. Business Model and Solutions - Hanbang Technology adopts a dual approach of product development and customized turnkey services, offering solutions for both small and large molecule drug separation and purification [7]. - The company provides tailored solutions based on client sample characteristics, optimizing chromatography filler performance to reduce production costs [7]. Financial Performance - The company's revenue has shown consistent growth, with figures of 482 million yuan, 619 million yuan, and 691 million yuan from 2022 to 2024, respectively [8]. - Net profit attributable to the parent company has also increased, reaching approximately 79.34 million yuan in 2024 [8]. Future Outlook - Hanbang Technology anticipates continued growth in the domestic liquid chromatography market, with the laboratory liquid chromatography market projected to reach 3.6 billion yuan by 2026 [8]. - The company plans to raise funds through an IPO to enhance production capacity and R&D capabilities, with specific projects aimed at increasing production of chromatography equipment and laboratory instruments [8][9]. - Future technical focuses include optimizing chromatography system pressure resistance, fluid distribution, sealing, and homogenization technologies, as well as developing higher selectivity chromatography materials [9].

江苏汉邦科技股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（主承销商）：中信证券股份有限公司 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，江苏汉邦科技股份有限公司（以下简称"汉邦 科技"、"公司"、"本公司"或"发行人"）发行的人民币普通股股票将于 2025 年 5 月 16 日在上海证券交易所科创板上市，上市公告书全文和首次公开发行股 票的招股说明书在上海证券交易所网站（http://www.sse.com.cn/）和符合中国证 监 会 规 定 条 件 网 站 （ 中 国 证 券 网 ， http://www.cnstock.com ； 中 证 网 ， http://www.cs.com.cn ； 证 券 时 报 网 ， http://www.stcn.com ； 证 券 日 报 网 ， http://www.zqrb.cn）披露，并置备于发行人、上交所、本次发行保荐人（主承销 商）中信证券股份有限公司的住所，供公众查阅。 一、上市概况 （一）股票简称：汉邦科技 （ ...

股票简称：汉邦科技 股票代码：688755 江苏汉邦科技股份有限公司 Jiangsu Hanbon Science and Technology Co., Ltd. （淮安经济技术开发区新竹路 10 号；淮安经济技术开发区集贤路 1-9 号） 首次公开发行股票科创板上市公告书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年五月十五日 江苏汉邦科技股份有限公司 上市公告书 特别提示 江苏汉邦科技股份有限公司（以下简称"汉邦科技"、"本公司"、"发 行人"、"公司"）股票将于 2025 年 5 月 16 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 1 江苏汉邦科技股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真 实、准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏， 并依法承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均 不表明 ...

江苏汉邦 日限公 (草案) 2023年 4月 4-2-1 t and the | 第一章 | 总 则 | | --- | --- | | 第二章 | 经营宗旨和范围 | | 第三章 | 股 价 | | 第四章 | 股东和股东大会 . | | 第五章 | 董事会 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………23 | | 第六章 | 总经理及其他高级管理人员 . | | 第七章 | 业事公 ………………………………………………………………………………………………………………35 | | 第八章 | 财务会计制度、利润分配和审计 . | | 第九章 | 通知和公告 | | 第十章 | 合并、分立、增资、减资、解散和清算 | | | 第十一章 修改章程. | | | 第十二章 附 则 ……………………………………………………………………………………………………………………………………………………………………………………… ...

Core Viewpoint - Hanbang Technology (688755.SH) is set to launch its IPO on May 7, 2023, with a price of 22.77 yuan per share, which corresponds to a P/E ratio of 26.35, slightly below the industry average of 28.04 and the comparable companies' average of 46.64 [1] Company Overview - Hanbang Technology, established in October 1998, focuses on chromatography technology, providing specialized separation and purification equipment, consumables, and technical solutions for the pharmaceutical and life sciences sectors [3] - The company aims to raise approximately 5.01 billion yuan through the issuance of 22 million shares, with a net fundraising amount expected to be around 4.31 billion yuan after deducting issuance costs [1] Financial Performance - Revenue for Hanbang Technology is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from approximately 38.56 million yuan to 79.34 million yuan during the same period [3][4] - The gross profit margin is expected to improve from 39.22% in 2022 to 42.46% in 2024 [3] - The company's total assets are projected to decrease from 1.40 billion yuan in 2022 to 1.32 billion yuan in 2024, while the equity attributable to shareholders is expected to rise from 566.92 million yuan to 739.63 million yuan [4] Revenue Composition - The primary revenue sources for Hanbang Technology are small molecule and large molecule drug separation and purification equipment, with small molecule equipment sales increasing from 49.75% of revenue in 2022 to 66.7% in 2024 [5][6] - The revenue from large molecule drug separation equipment is expected to decline from 44.46% in 2022 to 28% in 2024 [6] R&D and Accounts Receivable - R&D expenditures for Hanbang Technology were 28.99 million yuan, 37.18 million yuan, and 41.84 million yuan over the last three years, totaling 108 million yuan, which is 6.03% of cumulative revenue [8] - The accounts receivable at the end of the reporting periods were 131 million yuan, 119 million yuan, and 130 million yuan, with overdue accounts receivable making up a significant portion [8] Market Position and Risks - Hanbang Technology holds the leading market share in the domestic small molecule liquid chromatography system market, reaching 39.2% in 2023, but faces limited room for further growth [9] - The company is involved in ongoing patent infringement lawsuits with Cytiva, which could negatively impact its financial performance if the rulings are unfavorable [9]

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has officially launched its initial public offering (IPO) process, with the online and offline subscription date set for May 7, 2025 [1] Company Overview - Hanbang Technology is a high-tech enterprise focused on chromatography technology, providing specialized separation and purification equipment, consumables, application technology services, and related technical solutions primarily for the pharmaceutical and life sciences sectors [2][3] - The company is one of the earliest domestic manufacturers with complete independent intellectual property rights for liquid chromatography systems, breaking the long-standing foreign monopoly in related technologies and products [2] Market Position - According to Frost & Sullivan, the total market size for liquid chromatography equipment in China exceeded 2.7 billion yuan in 2023, with Hanbang Technology ranking second in the production-grade liquid chromatography separation equipment market, holding a market share of approximately 12.7% [2] - In the production-grade small molecule liquid chromatography system market, Hanbang Technology achieved a market share of 39.2% in a market size of approximately 780 million yuan in 2023 [2] - The company ranked third in the production-grade macromolecule chromatography system market, with a market share of about 8.8% in a market size of approximately 2.5 billion yuan in 2023 [2] Industry Growth Drivers - The chromatography equipment market is expanding globally, particularly in China, driven by the continuous development of application fields, domestic substitution, and rapid growth in downstream industries [3] - Since 2021, various national policies and regulations have been introduced to support the development of the pharmaceutical and scientific instrument sectors, creating a favorable operating environment for companies like Hanbang Technology [3] Financial Performance - Hanbang Technology's revenue has shown consistent growth from 321 million yuan in 2021 to an estimated 691 million yuan in 2024, while net profit attributable to shareholders increased from 4.86 million yuan to approximately 79.34 million yuan during the same period [3] R&D and Technological Strength - The company has focused on chromatography separation and purification products for nearly 30 years, with R&D investment increasing from 22.04 million yuan in 2021 to 41.84 million yuan in 2024 [4] - Hanbang Technology has developed several core technologies and holds 53 authorized invention patents, including 40 domestic and 13 overseas patents [4] IPO Fund Utilization - The funds raised from the IPO will be used to expand and deepen existing business operations, including projects for producing 1,000 units of liquid chromatography separation equipment, establishing a chromatography separation equipment R&D center, and producing 2,000 units of laboratory chromatography purification instruments [5][6]